Joint research team develops world's 1st oral microbiome-based nanodrug for cancer immunotherapy
Researchers at Sungkyunkwan University and the University of Michigan have developed the world’s first oral microbiome-based nanodrug for cancer immunotherapy. Sungkyunkwan University said Monday that the nanodrug significantly enhances the ability of immune cells to attack cancer cells by using natural metabolites produced by gut bacteria. The university’s research team, led by Cho Young-seok,…
Sungkyunkwan University and the University of Michigan researchers have created the world's first oral microbiome-based nanodrug for cancer immunotherapy. This nanodrug boosts the ability of immune cells to target cancer cells by utilizing natural metabolites produced by gut bacteria. Professor Cho Young-seok from Sungkyunkwan University's School of Medicine led the joint study with researchers from the University of Michigan, including Professor James J. Moon from the Department of Pharmaceutical Sciences.
Their findings were published in Nature Nanotechnology, a premier journal in nanoscience and medicine, under the title "Oral nano-delivery of a gut microbial metabolite enhances T cell stemness for cancer immunotherapy." Professor Cho explained that this study is the first to reveal how gut microbes in our bodies enhance immune function at the molecular level and translate this mechanism into an orally administered drug using nanotechnology.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
